Huan Qiu Wang·2026-02-26 08:36Core Insights - The clinical trial results for UBT251, a triple receptor agonist, show significant weight loss and improvements in various health metrics among overweight or obese patients in China [1][2] Group 1: Clinical Trial Results - UBT251 demonstrated a maximum average weight reduction of 19.7% (-17.5 kg) after 24 weeks compared to a 2.0% (-1.6 kg) reduction in the placebo group [1] - Statistically significant improvements were observed in key secondary endpoints, including waist circumference, blood glucose, blood pressure, and blood lipids, across all dosage groups of UBT251 compared to placebo [1] Group 2: Company Statements - The chairman of the company, Mr. Tsoi Hoi Shan, highlighted the success of the Phase II clinical trial as a significant milestone driven by innovation, emphasizing a focus on chronic diseases in the endocrine and metabolic fields [2] - Martin Holst Lange, the Chief Scientific Officer of Novo Nordisk, expressed encouragement from the trial data, noting the potential and differentiated clinical characteristics, safety, and tolerability of UBT251, with anticipation for global trial data to be released next year [2]